1-14 of 14
decitabine
Close
Sort by
Journal Articles

In MDS, is higher risk higher reward?

Guillermo F. Sanz
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 381–390.
https://doi.org/10.1182/hematology.2019000042
Published: 2019
Journal Articles

Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents

Olatoyosi Odenike
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 460–469.
https://doi.org/10.1182/asheducation-2017.1.460
Published: 2017
Journal Articles

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Amy E. DeZern
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 308–316.
https://doi.org/10.1182/asheducation-2015.1.308
Published: 2015
Journal Articles

Treating acute myeloid leukemia in older adults

Eunice S. Wang
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 14–20.
https://doi.org/10.1182/asheducation-2014.1.14
Published: 2014
Journal Articles

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

Yogen Saunthararajah
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 511–521.
https://doi.org/10.1182/asheducation-2013.1.511
Published: 2013
Journal Articles

Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology Am Soc Hematol Educ Program. 2012;2012: 65–73 .

Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 692.
https://doi.org/10.1182/asheducation.V2013.1.692.3851497a
Published: 2013
Journal Articles

Novel therapeutic strategies: hypomethylating agents and beyond

Valeria Santini
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 65–73.
https://doi.org/10.1182/asheducation.V2012.1.65.3806843
Published: 2012
Journal Articles

How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes

William Blum
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 314–321.
https://doi.org/10.1182/asheducation-2010.1.314
Published: 2010
Journal Articles

Clinical Issues in the Management of Patients with Myelodysplasia

Charles A. Schiffer
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 205–210.
https://doi.org/10.1182/asheducation-2006.1.205
Published: 2006
Journal Articles

Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease

Hassana Fathallah, George F. Atweh
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 58–62.
https://doi.org/10.1182/asheducation-2006.1.58
Published: 2006
Journal Articles

Update on Supportive Care and New Therapies: Immunomodulatory Drugs, Growth Factors and Epigenetic-Acting Agents

Eva Hellström-Lindberg
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 161–166.
https://doi.org/10.1182/asheducation-2005.1.161
Published: 2005
Journal Articles

Hemoglobinopathies

George F. Atweh, Joseph DeSimone, Yogen Saunthararajah, Hassana Fathallah, Rona S. Weinberg, Ronald L. Nagel, Mary E. Fabry, Robert J. Adams
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2003) 2003 (1): 14–39.
https://doi.org/10.1182/asheducation-2003.1.14
Published: 2003
Journal Articles

Myelodysplastic Syndrome

Ghulam Mufti, Alan F. List, Steven D. Gore, Aloysius Y.L. Ho
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2003) 2003 (1): 176–199.
https://doi.org/10.1182/asheducation-2003.1.176
Published: 2003
Journal Articles

Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies

Hagop Kantarjian, Junia V. Melo, Sante Tura, Sergio Giralt, Moshe Talpaz
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2000) 2000 (1): 90–109.
https://doi.org/10.1182/asheducation.V2000.1.90.90
Published: 2000